Allakos Inc.

3.66-0.2400-6.15%Vol 573.03K1Y Perf -95.13%
Aug 9th, 2022 16:00 DELAYED
BID3.50 ASK3.97
Open3.84 Previous Close3.90
Pre-Market- After-Market3.79
 - -  0.13 3.55%
Target Price
8.19 
Analyst Rating
Hold 2.73
Potential %
123.77 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★★★     56.68
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
1.02 
Earnings Rating
Neutral
Market Cap200.73M 
Earnings Date
8th Aug 2022
Alpha-0.01 Standard Deviation0.31
Beta0.86 

Today's Price Range

3.593.87

52W Range

2.54112.87

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
18.54%
1 Month
8.94%
3 Months
21.68%
6 Months
-42.82%
1 Year
-95.13%
3 Years
-95.41%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALLK3.66-0.2400-6.15
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.87-0.90-3.45
Q01 2022-1.71-3.60-110.53
Q04 2021-1.34-1.73-29.10
Q03 2021-1.12-1.16-3.57
Q02 2021-1.06-1.07-0.94
Q01 2021-0.78-1.04-33.33
Q04 2020-0.85-0.86-1.18
Q03 2020-0.83-0.86-3.61
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.8714.71Positive
9/2022 QR-0.7416.85Positive
12/2022 FY-5.74-18.60Negative
12/2023 FY-3.186.19Positive
Next Report Date-
Estimated EPS Next Report-0.87
Estimates Count6
EPS Growth Next 5 Years %32.50
Volume Overview
Volume573.03K
Shares Outstanding54.84K
Shares Float38.63M
Trades Count5.15K
Dollar Volume2.43M
Avg. Volume751.06K
Avg. Weekly Volume551.10K
Avg. Monthly Volume761.62K
Avg. Quarterly Volume940.45K

Allakos Inc. (NASDAQ: ALLK) stock closed at 3.9 per share at the end of the most recent trading day (a -2.26% change compared to the prior day closing price) with a volume of 616.45K shares and market capitalization of 200.73M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 114 people. Allakos Inc. CEO is Robert Alexander.

The one-year performance of Allakos Inc. stock is -95.13%, while year-to-date (YTD) performance is -60.16%. ALLK stock has a five-year performance of %. Its 52-week range is between 2.535 and 112.87, which gives ALLK stock a 52-week price range ratio of 1.02%

Allakos Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 0.76, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -82.97%, a ROC of -84.66% and a ROE of -97.75%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Allakos Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.87 for the next earnings report. Allakos Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Allakos Inc. is Hold (2.73), with a target price of $8.19, which is +123.77% compared to the current price. The earnings rating for Allakos Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Allakos Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Allakos Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 13.28, ATR14 : 0.42, CCI20 : 89.14, Chaikin Money Flow : 0.14, MACD : 0.09, Money Flow Index : 76.23, ROC : -10.14, RSI : 36.77, STOCH (14,3) : 58.96, STOCH RSI : 0.94, UO : 58.41, Williams %R : -41.04), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Allakos Inc. in the last 12-months were: Adam Tomasi (Option Excercise at a value of $276 638), Steven P. James (Option Excercise at a value of $2 100), Steven P. James (Sold 4 000 shares of value $432 480 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (27.27 %)
2 (18.18 %)
2 (20.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
6 (54.55 %)
7 (63.64 %)
6 (60.00 %)
Moderate Sell
1 (9.09 %)
1 (9.09 %)
1 (10.00 %)
Strong Sell
1 (9.09 %)
1 (9.09 %)
1 (10.00 %)
Summary RatingHold
2.73
Hold
2.91
Hold
2.90

Allakos Inc.

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells.

CEO: Robert Alexander

Telephone: +1 650 597-5002

Address: 975 Island Drive, Redwood City 94065, CA, US

Number of employees: 114

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

73%27%

Bearish Bullish

68%32%

Bearish Bullish

61%39%

TipRanks News for ALLK

Thu, 12 May 2022 12:34 GMT Allakos (ALLK) Gets a Hold Rating from SVB Securities

- TipRanks. All rights reserved.

News

Stocktwits